可植入医疗设备研发商Butterfly Medical获得 2100万美元C轮融资，用于推进微创BPH治疗的发展-动脉网

Butterfly Medical Secures $21 Million in Upsized Series C Funding to Advance Minimally Invasive BPH Treatment

CISION 等信源发布 2026-05-14 20:30



可切换为仅中文







Strategic Investment Fuels

战略性投资燃料

FDA Regulatory Path and Global Commercialization; Company to Showcase Technology at AUA 2026

FDA监管路径与全球商业化；公司将在AUA 2026展示技术

BOSTON and YOKNEAM, Israel

波士顿和以色列约克尼姆

，

May 14, 2026

2026年5月14日

/PRNewswire/ --

Butterfly Medical

蝴蝶医疗科技公司

, developer of a proprietary non-surgical solution for BPH (benign prostatic hyperplasia), today announced the successful completion of its Series C funding round, raising $21 million. The strong institutional demand validates the company's therapeutic approach and competitive positioning. The round includes participation from new and existing investors, including the European Innovation Council (EIC), Junson Capital, MedVenture and New Rhein Healthcare Investors..

，开发了针对良性前列腺增生（BPH）的专有非手术解决方案，今天宣布成功完成其C轮融资，筹集了2100万美元。强烈的机构需求验证了该公司的治疗方法和竞争定位。本轮投资包括来自新投资者和现有投资者的参与，其中包括欧洲创新委员会（EIC）、Junson Capital、MedVenture和New Rhein Healthcare Investors。

继续阅读

The Butterfly Prostatic Retraction Device.

蝴蝶前列腺牵开器。

'The success of this financing round, which exceeded our target, validates both the clinical potential and significant market opportunity for the Butterfly prostatic retraction device,' said Patrick MacCarthy, CEO of Butterfly Medical. 'With our pivotal trial now complete and U.S. regulatory filings underway, our focus is now on preparing for commercialization.

“本轮募资的成功，超出我们的预期目标，这验证了Butterfly前列腺回缩装置的临床潜力和巨大的市场机遇，”Butterfly Medical首席执行官Patrick MacCarthy说道。“随着我们关键试验的完成以及美国监管文件的提交，我们的重点现在放在准备商业化上。”

We look forward to working with the FDA to provide men suffering from BPH with a new solution designed to improve their quality of life.' .

我们期待与FDA合作，为患有BPH的男性提供一种旨在改善生活质量的新解决方案。

Butterfly Medical will be showcasing its technology at the American Urological Association (AUA) 2026 Annual Meeting in Washington, D.C. from May 15-18. Attendees are invited to visit the Butterfly Medical team at Booth #448 to learn more about the device and the company's clinical progress.

蝴蝶医疗公司将于5月15日至18日在华盛顿特区举行的美国泌尿协会（AUA）2026年年会上展示其技术。与会者可前往448号展位访问蝴蝶医疗团队，了解更多关于该设备及公司的临床进展。

The device, which has already secured CE Mark approval for use in Europe

该设备已获得欧洲使用的CE标志批准

，

is designed to alleviate the common and debilitating symptoms of BPH, which affects a large and growing population of men globally. It is a minimally invasive, implantable solution that mechanically retracts the lateral lobes of the prostate to restore urine flow. This proprietary, anatomically designed mechanism is intended to restore and maintain natural urinary flow without the need for cutting, burning or removing tissue, while also being fully reversible..

旨在缓解影响全球大量且日益增多的男性人群的良性前列腺增生（BPH）常见且令人痛苦的症状。它是一种微创、可植入的解决方案，通过机械收缩前列腺的侧叶来恢复尿流。这种专有的、基于解剖学设计的机制旨在无需切割、烧灼或去除组织的情况下恢复并维持自然的尿流，同时还可以完全逆转。

'We are impressed by both the quality of the team and the financial efficiency of Butterfly Medical's development efforts, which have achieved a stage similar to other minimally invasive BPH solutions with less than half the capital,' said Nayan Parekh, PhD, Managing Partner at New Rhein Healthcare Investors and Chairman of the Board at Butterfly Medical.

“我们对团队的质量和Butterfly Medical开发工作的财务效率印象深刻，该公司以不到一半的资金达到了与其它微创BPH解决方案相似的阶段，”New Rhein Healthcare Investors的管理合伙人、Butterfly Medical董事会主席Nayan Parekh博士说道。

'Based on the platform's clinical data, ease of use, competitive COGS, and zero durable capital equipment, we are excited about the potential for this technology to achieve significant market adoption.'.

“基于该平台的临床数据、易用性、有竞争力的成本以及无需耐用资本设备，我们对这项技术实现显著的市场应用潜力感到兴奋。”

About Butterfly Medical

关于蝴蝶医疗

Butterfly Medical is a medical device company committed to reshaping the treatment of benign prostatic hyperplasia (BPH) through its innovative, non-surgical solution. The company's flagship product is designed to restore natural urinary flow to provide significant, long-term relief from BPH symptoms, thereby improving patients' quality of life.

Butterfly Medical是一家致力于通过其创新的非手术解决方案重塑良性前列腺增生（BPH）治疗的医疗设备公司。该公司的旗舰产品旨在恢复自然尿流，为BPH症状提供显著的长期缓解，从而改善患者的生活质量。

The Butterfly.

蝴蝶。

Medical device is CE Mark certified and not yet approved in the U.S., limited by federal law to investigational use. By offering an alternative to both medication and conventional BPH surgery, Butterfly Medical aims to improve the standard of care for millions of men worldwide.

医疗器械已获得CE标志认证，但尚未在美国获得批准，根据联邦法律限制为研究用途。通过提供药物和传统BPH手术的替代方案，Butterfly Medical旨在改善全球数百万男性的护理标准。

For more information, visit:

欲了解更多信息，请访问：

https://butterfly-medical.com/

. Follow Butterfly Medical on

关注Butterfly Medical

领英

。

Media Contact:

媒体联系人:

Ellie Hanson

艾莉·汉森